Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections
|ClinicalTrials.gov Identifier: NCT00156377|
Recruitment Status : Completed
First Posted : September 12, 2005
Last Update Posted : May 25, 2010
|Condition or disease||Intervention/treatment||Phase|
|Cross Infection Staphylococcal Infections||Drug: Mupirocin||Phase 4|
In a past study, we showed that there is a strong correlation between strains colonizing the anterior nares, strains isolated from the presumed foci of infection, and strains isolated from blood in patients with Staphylococcus aureus bacteremia. These results suggested that a substantial proportion of cases of systemic S. aureus infections appear to be of endogenous origin and that eradication of nasal colonization should be the chief strategy for reducing the incidence of hospital-acquired S. aureus infections.
In order to evaluate the effect of eliminating nasal carriage by mupirocin prophylaxis on subsequent S. aureus infection, a prospective randomized trial was performed particularly including patients with predisposing risk factors for S. aureus infections. All patients admitted to selected units in clinics for anaesthesiology, hemato-oncology, cardiac surgery, and orthopedics at the University Hospital of Muenster were regularly screened for nasal carriage, i.e. at admission and, subsequently, on a weekly basis. S. aureus carrying patients were prospectively randomized, to be either treated with mupirocin for 5 days, or left untreated. Patients infected with S. aureus at admission and patients detected to be MRSA carrier were excluded from randomization.
Patients were regularly seen during the course of their hospital stay and predisposing/conditional risk factors were systematically documented. In both groups (untreated patients and patients with mupirocin prophylaxis), all nosocomial infections were documented according to CDC guidelines. If infected, specimens were taken for microbiological diagnosis. All S. aureus isolates (from the anterior nares as well as from the focus of infection) were collected and were genotyped.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Investigation of the Influence of Intranasal Mupirocin on the Prevalence of S. Aureus Nosocomial Infections by Eradication of Intranasal S. Aureus|
|Study Start Date :||November 2002|
- Staphylococcus aureus infection any time after 5 days of mupirocin ointment
- Presence or abscence of risk factors associated with S. aureus infections at any time during the hospital stay
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00156377
|Institute of Medical Microbiology, University Hospital of Muenster|
|Muenster, Germany, 48149|
|Principal Investigator:||Christof von Eiff, MD||University Hospital of Muenster, Institute of Medical Microbiology|